OpGen (NASDAQ: OPGN)

Currency in USD

Last close As at 22/09/2023

USD0.23

−0.01 (−4.17%)

Market capitalisation

USD2m

OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.

It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.

Latest Insights

View More

Healthcare | Update

OpGen — Cash concerns dampen active Q2

Healthcare | Flash note

OpGen — FIND collaboration advances to development

Healthcare | Flash note

OpGen — Feasibility milestone from FIND collaboration

Healthcare | Update

OpGen — Optimistic start to kick off a promising year

Laboratory Opgen

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Albert Weber

    CFO

  • Oliver Schacht

    CEO

Balance Sheet

Forecast net debt (US$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 12.5 (64.3) (97.3)
Relative 14.3 (64.0) (97.7)
52 week high/low US$8.3/US$0.2

Financials

OpGen is a diagnostics company focused on the identification and treatment of bacterial infections. Its portfolio of molecular diagnostic tests includes the Unyvero platform with five CE-IVD-marked tests and two FDA-cleared cartridges; Ares Genetics’ next-generation antimicrobial resistance (AMR) testing services; the 510(k) cleared Acuitas AMR Gene Panel in bacterial isolates; and ARES Genetics (NGS and bioinformatics platform). Its products are differentiated by a short turnaround time, the detection of a large range of pathogens and AMR profiling. OpGen recently announced a non-exclusive US distribution agreement with Fisher Healthcare and the extension of the FIND collaboration to development stage, both key developments. It reported 23.9% y-o-y top-line growth in Q223, but a short cash runway into September 2023 raises the going concern risk.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2021A 4.3 (20.4) (35.7) (1946.77) N/A N/A
2022A 2.6 (20.6) (25.3) (1036.81) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

OpGen — Optimistic start to kick off a promising year

Flash note

Healthcare

OpGen — $3.5m fund-raise to extend runway

Flash note

Healthcare

OpGen — FIND agreement milestones achieved

Flash note

Healthcare

OpGen — Expansion of FIND R&D collaboration

Laboratory Opgen

Flash note

Healthcare

OpGen — Interim milestone achieved for R&D collaboration

Update

Healthcare

OpGen — Forecasts reset ahead of busy 2023

Laboratory Opgen

Flash note

Healthcare

OpGen — FY22 wrap offers key operational takeaways

Further insights

insight

Healthcare

An update on OpGen: Deals, expansion and revenues

insight

Healthcare

Healthcare Week 2023

insight

Healthcare

OpGen CEO Oliver Schacht on OpGen’s $15m capital raise

insight

Healthcare

Nine things investors need to know about OpGen

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Thematics

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Healthcare

Machine learning in drug development

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free